ArticleRadiology. Imaging cancer2026
Association between Three-dimensional Margin Assessment and Local Tumor Control in Percutaneous Lung Cryoablation of Colorectal Metastases.
Article in Radiology. Imaging cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Outcomes following different thermal ablation strategies in patients with oligometastatic colorectal lung metastases.Frontiers in oncology · 2026Article
- Cryoablation combined with immunotherapy: new strategies and progress in the treatment of tumors.Frontiers in oncology · 2026Review
- Integrating Precision Margin Assessment with Minimally Invasive Therapies: New Frontiers in Image-guided Oncology.Radiology. Imaging cancer · 2026Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
Purpose To evaluate the association of two minimum ablation margin (MAM) estimation methods: manual three-dimensional segmentation and biomechanical deformable image registration (DIR) with local tumor progression-free survival (LTPFS) after percutaneous lung cryoablation of colorectal pulmonary metastases. Materials and Methods This retrospective single-institution study included patients who underwent percutaneous lung cryoablation between May 2012 and March 2023 (median follow-up, 3.6 years; range, 0.8-9.6 years). Manual three-dimensional MAM was calculated for all tumors, and DIR-based MAM was estimated in a subset with intraprocedural full-thorax imaging. Cox proportional hazards regression assessed associations between MAM and LTPFS. The primary outcome was 2-year LTPFS, with a secondary outcome of whether DIR-based MAM was associated with LTPFS. Results Thirty-eight patients (76 colorectal pulmonary metastases in 63 procedures; mean age, 58 years ± 12 [SD]; 19 female patients) were included. Technical success was 100% (63 of 63). Per-lesion LTPFS at 1 and 2 years was 87% and 84%. Five tumors (6.6%; five of 76) had no margin (0 mm), 55 tumors (72%; 55 of 76) had a MAM 0-5 mm, and 16 (21%; 16 of 76) had an MAM greater than 5 mm. Median LTPFS was 6 months for the 0-mm group and was not reached for the MAM 0-5-mm and the greater than 5-mm groups (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.